Truist analyst Gregory Renza initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $51 price target The company’s Lisaftoclax is differentiated by improved tolerability and accelerated 5-day dose ramp-up, which is clinically meaningful, according to key opinion leaders, the analyst tells investors in a research note. Growth in China depends on the NRDL inclusion by the end of 2027, and the firm views GLORA’s readout 2025-end or 2026E as key to supporting U.S. expansion in second-line CLL/SLL, or chronic lymphocytic leukemia/small lymphocytic lymphoma, the firm added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma to Engage Investors at December 2025 Conferences
- Ascentage Pharma initiated with a Buy at BTIG
- Pinterest downgraded, Tractor Supply upgraded: Wall Street’s top analyst calls
- Ascentage Pharma initiated with an Overweight at Piper Sandler
- Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks